Postinjection Muscle Fibrosis from Lupron
We describe the case of a 6.5-year-old girl with central precocious puberty (CPP), which signifies the onset of secondary sexual characteristics before the age of eight in females and the age of nine in males as a result of stimulation of the hypothalamic-pituitary-gonadal axis. Her case is likely r...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Case Reports in Pediatrics |
| Online Access: | http://dx.doi.org/10.1155/2015/938264 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850235068741582848 |
|---|---|
| author | Erica Everest Laurie A. Tsilianidis Nouhad Raissouni Tracy Ballock Terra Blatnik Anzar Haider Douglas G. Rogers B. Michelle Schweiger |
| author_facet | Erica Everest Laurie A. Tsilianidis Nouhad Raissouni Tracy Ballock Terra Blatnik Anzar Haider Douglas G. Rogers B. Michelle Schweiger |
| author_sort | Erica Everest |
| collection | DOAJ |
| description | We describe the case of a 6.5-year-old girl with central precocious puberty (CPP), which signifies the onset of secondary sexual characteristics before the age of eight in females and the age of nine in males as a result of stimulation of the hypothalamic-pituitary-gonadal axis. Her case is likely related to her adoption, as children who are adopted internationally have much higher rates of CPP. She had left breast development at Tanner Stage 2, adult body odor, and mildly advanced bone age. In order to halt puberty and maximize adult height, she was prescribed a gonadotropin releasing hormone analog, the first line treatment for CPP. She was administered Lupron (leuprolide acetate) Depot-Ped (3 months) intramuscularly. After her second injection, she developed swelling and muscle pain at the injection site on her right thigh. She also reported an impaired ability to walk. She was diagnosed with muscle fibrosis. This is the first reported case of muscle fibrosis resulting from Lupron injection. |
| format | Article |
| id | doaj-art-0f28f90af79e400a804bd9a7cc1325e9 |
| institution | OA Journals |
| issn | 2090-6803 2090-6811 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Pediatrics |
| spelling | doaj-art-0f28f90af79e400a804bd9a7cc1325e92025-08-20T02:02:25ZengWileyCase Reports in Pediatrics2090-68032090-68112015-01-01201510.1155/2015/938264938264Postinjection Muscle Fibrosis from LupronErica Everest0Laurie A. Tsilianidis1Nouhad Raissouni2Tracy Ballock3Terra Blatnik4Anzar Haider5Douglas G. Rogers6B. Michelle Schweiger7Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USACleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USAWe describe the case of a 6.5-year-old girl with central precocious puberty (CPP), which signifies the onset of secondary sexual characteristics before the age of eight in females and the age of nine in males as a result of stimulation of the hypothalamic-pituitary-gonadal axis. Her case is likely related to her adoption, as children who are adopted internationally have much higher rates of CPP. She had left breast development at Tanner Stage 2, adult body odor, and mildly advanced bone age. In order to halt puberty and maximize adult height, she was prescribed a gonadotropin releasing hormone analog, the first line treatment for CPP. She was administered Lupron (leuprolide acetate) Depot-Ped (3 months) intramuscularly. After her second injection, she developed swelling and muscle pain at the injection site on her right thigh. She also reported an impaired ability to walk. She was diagnosed with muscle fibrosis. This is the first reported case of muscle fibrosis resulting from Lupron injection.http://dx.doi.org/10.1155/2015/938264 |
| spellingShingle | Erica Everest Laurie A. Tsilianidis Nouhad Raissouni Tracy Ballock Terra Blatnik Anzar Haider Douglas G. Rogers B. Michelle Schweiger Postinjection Muscle Fibrosis from Lupron Case Reports in Pediatrics |
| title | Postinjection Muscle Fibrosis from Lupron |
| title_full | Postinjection Muscle Fibrosis from Lupron |
| title_fullStr | Postinjection Muscle Fibrosis from Lupron |
| title_full_unstemmed | Postinjection Muscle Fibrosis from Lupron |
| title_short | Postinjection Muscle Fibrosis from Lupron |
| title_sort | postinjection muscle fibrosis from lupron |
| url | http://dx.doi.org/10.1155/2015/938264 |
| work_keys_str_mv | AT ericaeverest postinjectionmusclefibrosisfromlupron AT laurieatsilianidis postinjectionmusclefibrosisfromlupron AT nouhadraissouni postinjectionmusclefibrosisfromlupron AT tracyballock postinjectionmusclefibrosisfromlupron AT terrablatnik postinjectionmusclefibrosisfromlupron AT anzarhaider postinjectionmusclefibrosisfromlupron AT douglasgrogers postinjectionmusclefibrosisfromlupron AT bmichelleschweiger postinjectionmusclefibrosisfromlupron |